Evidence map›Paper›PMID 23871823›Full record

ArticleVaccine2014

Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England.

Nigel Field, Gayatri Amirthalingam, Pauline Waight, Nick Andrews, Shamez N Ladhani, Albert Jan van Hoek, Peter A C Maple, Kevin E Brown, Elizabeth Miller

Open access · hybridAbstract readValidation Study
In one paragraph

Article in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nigel FieldImmunisation, Hepatitis and Blood Safety Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom(1); Research Department of Infection & Population Health, University College London, Mortimer Market Centre, Off Capper Street, London WC1E 6JB, United Kingdom. Electronic address: nigel.field@ucl.ac.uk.
Gayatri AmirthalingamImmunisation, Hepatitis and Blood Safety Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom(1).
Pauline WaightImmunisation, Hepatitis and Blood Safety Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom(1).
Nick AndrewsStatistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom(1).
Shamez N LadhaniImmunisation, Hepatitis and Blood Safety Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom(1).
Albert Jan van HoekImmunisation, Hepatitis and Blood Safety Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom(1).
Peter A C MapleVirus Reference Department, HPA Microbiology Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom(1).
Kevin E BrownVirus Reference Department, HPA Microbiology Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom(1).
Elizabeth MillerImmunisation, Hepatitis and Blood Safety Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom(1).
Mortimer Market Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn the UK, primary varicella is usually a mild infection in children, but can cause serious illness in susceptible pregnant women and adults. The UK Joint Committee on Vaccination and Immunisation is considering an adolescent varicella vaccination programme. Cost-effectiveness depends upon identifying susceptibles and minimising vaccine wastage, and chickenpox history is one method to screen for eligibility. To inform this approach, we estimated the proportion of adolescents with varicella antibodies by reported chickenpox history.

methodsRecruitment occurred through secondary schools in England from February to September 2012. Parents were asked about their child's history of chickenpox, explicitly setting the context in terms of the implications for vaccination. 247 adolescents, whose parents reported positive (120), negative (77) or uncertain (50) chickenpox history provided oral fluid for varicella zoster virus-specific immunoglobulin-G (VZV-IgG) testing.

results109 (90.8% [85.6-96.0%]) adolescents with a positive chickenpox history, 52 (67.5% [57.0-78.1%]) with a negative history and 42 (84.0% [73.7-94.3%]) with an uncertain history had VZV-IgG suggesting prior infection. Combining negative and uncertain histories, 74% had VZV-IgG (best-case). When discounting low total-IgG samples and counting equivocals as positive (worst-case), 84% had VZV-IgG. We also modelled outcomes by varying the negative predictive value (NPV) for the antibody assay, and found 74-87% under the best-case and 84-92% under the worst-case scenario would receive vaccine unnecessarily as NPV falls to 50%.

conclusionReported chickenpox history discriminates between varicella immunity and susceptibility in adolescents, but significant vaccine wastage would occur if this approach alone were used to determine vaccine eligibility. A small but important proportion of those with positive chickenpox history would remain susceptible. These data are needed to determine whether reported history, with or without oral fluid testing in those with negative and uncertain history, is sufficiently discriminatory to underpin a cost-effective adolescent varicella vaccination programme.

Indexed as

Medical History TakingAdolescentAntibodies, ViralChickenpoxChickenpox VaccineChildCost-Benefit AnalysisEnglandHumansImmunization ProgramsImmunoglobulin GPredictive Value of TestsAntibodies, ViralChickenpox VaccineImmunoglobulin GAdolescentChickenpoxReported historyVaccination programmeValidityVaricella

Identifiers

PMID23871823
PMCPMC3969712
OpenAlexW2128707719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.